Skip to main content

Advertisement

SpringerLink
Log in

Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis

  • REVIEW ARTICLE
  • Published:
Modern Rheumatology

Abstract

Application of biological agents targeting tumor necrosis factor-α (TNF-α) caused a paradigm shift in the treatment of rheumatoid arthritis (RA). The introduction of infliximab in 2003 and etanercept in 2005 in Japan had a significant impact on both Japanese rheumatologists and RA patients, although serious adverse effects such as bacterial pneumonia, tuberculosis and Pneumocystis jiroveci pneumonia are significant concerns. Based on the data from post-marketing surveillance in Japan and accumulating evidence worldwide, the Internal Medicine Rheumatology Study Group of the Ministry of Health, Labor and Welfare (MHLW), Japan, has updated the guidelines for the use of anti-TNF-α agents for RA, which were subsequently approved by the Board of Japan College of Rheumatology (JCR). In the present revised guidelines, we combined the guidelines for use of each of infliximab and etanercept together with some modifications and precautions, paying special attention to serious adverse reactions. Although it is still controversial whether the use of TNF-α blocking agents per se increases the risk of infection or not, bacterial pneumonia, regardless of the pathogens, is the most frequent complications in RA. The risk factors associated with pneumonia identified in the post-marketing surveillance of infliximab in Japan are presented in this guideline. The diagnostic algorithm is also designed for early diagnosis and treatment of pulmonary lesions seen during the treatment of biological agents. Preventive measures and precautions against tuberculosis, another frequent and significant complication in Japan, are also described. Furthermore, risk factors for developing Pneumocystis pneumonia, which uniquely occurs at 30- to 50-fold frequency under TNF-α blockade therapy in Japan, are described here and its preventive measures are discussed. It is stressed that secondary-care rheumatologists should be better familiarized with the proper use of TNF-α blocking agents and be alert to any adverse events for a better management of RA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. N Miyasaka T Takeuchi K Eguchi (2005) ArticleTitleJapanese guidelines for the use of infliximab for rheumatoid arthritis Mod Rheumatol 15 4–8 Occurrence Handle17028815 Occurrence Handle10.1007/s10165-004-0357-7 Occurrence Handle1:CAS:528:DC%2BD2MXhsV2is7k%3D

    Article  PubMed  CAS  Google Scholar 

  2. N Miyasaka T Takeuchi K Eguchi (2006) ArticleTitleGuidelines for the proper use of etanercept in Japan Mod Rheumatol 16 63–7 Occurrence Handle16633923 Occurrence Handle10.1007/s10165-006-0457-7 Occurrence Handle1:CAS:528:DC%2BD28XjslKit7o%3D

    Article  PubMed  CAS  Google Scholar 

  3. Information for proper use of infliximab (in Japanese) by Tanabe Seiyaku. http://medical.tanabe.co.jp/mstaff/remicade/index_remicade.shtml

  4. Information for proper use of etanercept. Vol. 4 (in Japanese) by Wyeth and Takeda Yakuhin, June 2006

  5. InstitutionalAuthorNameAmerican College of Rheumatology subcommittee on Rheumatoid Arthritis Guidelines (2002) ArticleTitleGuidelines for the management of rheumatoid arthritis Arthritis Rheum 46 328–46 Occurrence Handle10.1002/art.10148 Occurrence Handle1:CAS:528:DC%2BD38XhvF2ru7o%3D

    Article  CAS  Google Scholar 

  6. DE Furst FC Breedveld JR Kalden JS Smolen GR Burmeater JWJ Bijlsma et al. (2005) ArticleTitleUpdated consensus statement on biological agents, specifically tumor necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Ann Rheum Dis 64 iv2–iv14 Occurrence Handle16239380 Occurrence Handle10.1136/ard.2005.044941 Occurrence Handle1:CAS:528:DC%2BD2MXht1amtL7L

    Article  PubMed  CAS  Google Scholar 

  7. J Ledingham C Deighton (2005) ArticleTitleUpdate on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) Rheumatology 44 157–63 Occurrence Handle15637039 Occurrence Handle10.1093/rheumatology/keh464 Occurrence Handle1:STN:280:DC%2BD2M%2FlsVSksA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  8. Japan College of Rheumatology, Official Guidelines for the use of anti-TNF agents for rheumatoid arthritis (in Japanese). https://www.ryumachi-jp.com/Ryumachi/Secure/kaiin/medical/brm_guideline.html

  9. FC Arnett SM Edworthy DA Bloch DJ McShane JF Fries NS Cooper et al. (1988) ArticleTitleThe American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315–24 Occurrence Handle3358796 Occurrence Handle10.1002/art.1780310302 Occurrence Handle1:STN:280:DyaL1c7pt1Ohsg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  10. Study Group of the Ministry of Health, Labour and Welfare. Diagnostic and therapeutic manual of rheumatoid arthritis. Diagnostic manual and evidence-based treatment guidelines (in Japanese). Japan Rheumatism Foundation; 2004

  11. J McCurry (2004) ArticleTitleJapan deaths spark concerns over arthritis drug Lancet 363 461 Occurrence Handle14964006 Occurrence Handle10.1016/S0140-6736(04)15527-X

    Article  PubMed  Google Scholar 

  12. F Sakai S Noma Y Kurihara H Yamada A Azuma S Kudoh et al. (2005) ArticleTitleLeflunomide-related lung injury in patients with rheumatoid arthritis: imaging features Mod Rheumatol 15 173–9 Occurrence Handle17029058 Occurrence Handle10.1007/s10165-005-0387-9

    Article  PubMed  Google Scholar 

  13. J Ogawa M Harigai K Nagasaka T Nakamura N Miyasaka (2005) ArticleTitlePrediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy Mod Rheumatol 15 91–6 Occurrence Handle17029042 Occurrence Handle10.1007/s10156-004-0368-5 Occurrence Handle1:CAS:528:DC%2BD2MXjvVCntbw%3D

    Article  PubMed  CAS  Google Scholar 

  14. T Obayashi M Yoshida T Mori H Goto A Yasuoka H Iwasaki et al. (1995) ArticleTitlePlasma (1→3)-β-glucan measurement in diagnosis of invasive deep mycosis and fungi febrile episodes Lancet 345 17–20 Occurrence Handle7799700 Occurrence Handle10.1016/S0140-6736(95)91152-9 Occurrence Handle1:STN:280:DyaK2M%2FpslKrsw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  15. A Yasuoka N Tachikawa K Shimada S Kimura S Oka (1996) ArticleTitle(1→3) β-d-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia Clin Diagn Lab Immnunol 3 197–9 Occurrence Handle1:CAS:528:DyaK28Xitlaiuro%3D

    CAS  Google Scholar 

  16. K Saito S Nakayamada K Nakano M Tokunaga S Tsujimura K Nakatsuka et al. (2004) ArticleTitleDetection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: reevaluation of clinical features of P. carinii pneumonia in rheumatic diseases Rheumatology 43 479–85 Occurrence Handle14762223 Occurrence Handle10.1093/rheumatology/keh071 Occurrence Handle1:CAS:528:DC%2BD2cXitlyhsb4%3D

    Article  PubMed  CAS  Google Scholar 

  17. LH Calabrese NN Zein D Vassilopoulos (2006) ArticleTitleHepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies Ann Rheum Dis 65 983–9 Occurrence Handle16627542 Occurrence Handle10.1136/ard.2005.043257 Occurrence Handle1:CAS:528:DC%2BD28XosFahur4%3D

    Article  PubMed  CAS  Google Scholar 

  18. RS Wallis MS Broder JY Wong ME Hanson DO Beenhouwer (2004) ArticleTitleGranulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 1261–5 Occurrence Handle15127338 Occurrence Handle10.1086/383317 Occurrence Handle1:STN:280:DC%2BD2c3islCksg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  19. NF Crum ER Lederman MR Wallace (2005) ArticleTitleInfections associated with tumor necrosis factor-α antagonists Medicine 84 291–302 Occurrence Handle16148729 Occurrence Handle10.1097/01.md.0000180044.19285.9a Occurrence Handle1:CAS:528:DC%2BD2MXpslCmtLk%3D

    Article  PubMed  CAS  Google Scholar 

  20. AH Mufti BW Toye RRJ Mckendry JB Angel (2005) ArticleTitle Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use Diagn Microbiol Infect Dis 53 233–8 Occurrence Handle16249064 Occurrence Handle10.1016/j.diagmicrobio.2005.06.006 Occurrence Handle1:CAS:528:DC%2BD2MXht1SksLrF

    Article  PubMed  CAS  Google Scholar 

  21. D Khanna M McMahon DE Furst (2004) ArticleTitleSafety of tumour necrosis factor-α antagonists Drug Safety 27 307–24 Occurrence Handle15061685 Occurrence Handle10.2165/00002018-200427050-00003 Occurrence Handle1:CAS:528:DC%2BD2cXkt1Shurg%3D

    Article  PubMed  CAS  Google Scholar 

  22. CA Benson JE Kaplan H Masur A Pau KK Holmes (2004) ArticleTitleTreating opportunistic infections among HIV-infected adults and adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Associated Diseases Society of America MMWR 53 IssueIDRR15 1–112 Occurrence Handle15841069

    PubMed  Google Scholar 

  23. ES Chung M Packer KH Lo AA Fasanmade JT Willerson (2003) ArticleTitleRandomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial Circulation 107 3133–40 Occurrence Handle12796126 Occurrence Handle10.1161/01.CIR.0000077913.60364.D2 Occurrence Handle1:CAS:528:DC%2BD3sXkslKgtrs%3D

    Article  PubMed  CAS  Google Scholar 

  24. HJ Kwon TR Cote MS Cuffe JM Kramer MM Braun (2003) ArticleTitleCase reports of heart failure after therapy with a tumor necrosis factor antagonist Ann Intern Med 138 807–12 Occurrence Handle12755552

    PubMed  Google Scholar 

  25. InstitutionalAuthorNameThe Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) ArticleTitleTNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study Neurology 53 457–65

    Google Scholar 

  26. N Mohan ET Edwards TR Cupps PJ Oliverio G Sandberg H Crayton et al. (2001) ArticleTitleDemyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides Arthritis Rheum 44 2862–9 Occurrence Handle11762947 Occurrence Handle10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W Occurrence Handle1:CAS:528:DC%2BD38XislCltA%3D%3D

    Article  PubMed  CAS  Google Scholar 

  27. J Jarand DW Zochodne LO Martin C Voll (2006) ArticleTitleNeurological complications of infliximab J Rheumatol 33 1018–20 Occurrence Handle16511935

    PubMed  Google Scholar 

  28. EA Carswell LJ Old RL Kassel S Green N Fiore B Williamson (1975) ArticleTitleAn endotoxin-induced serum factor that causes necrosis of tumors Proc Nat Acad Sci USA 72 3666–70 Occurrence Handle1103152 Occurrence Handle10.1073/pnas.72.9.3666 Occurrence Handle1:STN:280:DyaE28%2FltlWrtg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  29. K Bendtzen P Geborek M Svenson L Larsson MC Kapetanovic T Saxne (2006) ArticleTitleIndividualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab Arthritis Rheum 54 3782–9 Occurrence Handle17133559 Occurrence Handle10.1002/art.22214 Occurrence Handle1:CAS:528:DC%2BD2sXktlanug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  30. L Klareskog D Van der Heijde JP De Jager A Gough J Kalden M Malaise et al. (2004) ArticleTitleTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675–81 Occurrence Handle15001324 Occurrence Handle10.1016/S0140-6736(04)15640-7 Occurrence Handle1:CAS:528:DC%2BD2cXhs12jur4%3D

    Article  PubMed  CAS  Google Scholar 

  31. MF Doran CS Crowson GR Pond WM O'Fallon SE Gabrial (2002) ArticleTitlePredictors of infection in rheumatoid arthritis Arthritis Rheum 46 2294–300 Occurrence Handle12355476 Occurrence Handle10.1002/art.10529

    Article  PubMed  Google Scholar 

  32. F Wolfe L Caplan K Michaud (2006) ArticleTitleTreatment of rheumatoid arthritis and the risk of hospitalization for pneumonia. Association with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy Arthritis Rheum 54 628–34 Occurrence Handle16447241 Occurrence Handle10.1002/art.21568 Occurrence Handle1:CAS:528:DC%2BD28XhvFKhsbY%3D

    Article  PubMed  CAS  Google Scholar 

  33. S Kroesen AF Widmer A Tyndall P Hasler (2003) ArticleTitleSerious bacterial infections in patients with rheumatoid arthritis under anti-TNF-α therapy Rheumatology 42 617–21 Occurrence Handle12709536 Occurrence Handle10.1093/rheumatology/keg263 Occurrence Handle1:CAS:528:DC%2BD3sXjtlGnu7c%3D

    Article  PubMed  CAS  Google Scholar 

  34. J Listing A Strangfeld S Kary R Rau U Von Hinueber M Stoyanova-Scholz et al. (2005) ArticleTitleInfections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 52 3403–12 Occurrence Handle16255017 Occurrence Handle10.1002/art.21386 Occurrence Handle1:CAS:528:DC%2BD2MXht1KrtbfF

    Article  PubMed  CAS  Google Scholar 

  35. WG Dixon K Watson M Lunt KL Hyrich InstitutionalAuthorNameBritish Society for Rheumatology Biologics Register Control Centre Consorium AJ Silman et al. (2006) ArticleTitleRates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy Arthritis Rheum 54 2368–76 Occurrence Handle16868999 Occurrence Handle10.1002/art.21978 Occurrence Handle1:CAS:528:DC%2BD28XpsFGgu7g%3D

    Article  PubMed  CAS  Google Scholar 

  36. R Westhovens D Yocum J Han A Berman I Strusberg P Geusens et al. (2006) ArticleTitleThe safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large, randomized, placebo-controlled trial Arthritis Rheum 54 1075–86 Occurrence Handle16572442 Occurrence Handle10.1002/art.21734 Occurrence Handle1:CAS:528:DC%2BD28XksVyht7s%3D

    Article  PubMed  CAS  Google Scholar 

  37. L Carmona JJ Gomez-Reino V Rodriguez-Valverde D Montero E Pascual-Gomez EE Mola et al. (2005) ArticleTitleEffectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 1766–72 Occurrence Handle15934089 Occurrence Handle10.1002/art.21043 Occurrence Handle1:CAS:528:DC%2BD2MXlvFChur0%3D

    Article  PubMed  CAS  Google Scholar 

  38. Label approved on 06/12/2007 of REMICADE, FDA homepage. Available from: URL: http://www.fda.gov/cder/foi/label/2007/103772s5189lbl.pdf

  39. Label approved on 02/01/2007 of ENBREL, FDA homepage. Available from: URL: http://www.fda.gov/cder/foi/label/2007/103795s5322lbl.pdf

  40. A Wollner J Mohle-Boetani E Lambert JL Perruquet TA Raffin JL McGuire (1991) ArticleTitle Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for rheumatoid arthritis Thorax 46 205–7 Occurrence Handle2028435 Occurrence Handle1:STN:280:DyaK3M3ivVWgtw%3D%3D Occurrence Handle10.1136/thx.46.3.205

    Article  PubMed  CAS  Google Scholar 

  41. TL Tai KP O'Rourke M McWeeney CM Burke K Sheehan M Barry (2002) ArticleTitle Pneumocystis carinii pneumonia following a second infusion of infliximab Rheumatology 41 951–2 Occurrence Handle12154220 Occurrence Handle10.1093/rheumatology/41.8.951 Occurrence Handle1:STN:280:DC%2BD38vgsV2jtw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  42. T Lequerre O Vittecoq N Klemmer V Goeb S Pouplin J-F Menard et al. (2006) ArticleTitleManagement of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology J Rheumatol 33 1307–14 Occurrence Handle16758513 Occurrence Handle1:CAS:528:DC%2BD28XnslWjt7s%3D

    PubMed  CAS  Google Scholar 

  43. MedWatch, FDA home page. Available from: URL: http://www.fda.gov/medwatch/SAFETY/1998/inflix.htm

  44. S Kugathasan MB Levy K Saeian S Vasilopoulos JP Kim D Prajapati et al. (2002) ArticleTitleInfliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction Am J Gastroenterol 97 1408–14 Occurrence Handle12094858 Occurrence Handle10.1111/j.1572-0241.2002.05784.x Occurrence Handle1:CAS:528:DC%2BD2MXjtFOqsro%3D

    Article  PubMed  CAS  Google Scholar 

  45. F Sugiura T Kojima M Oba H Tsuchiya N Ishiguro (2005) ArticleTitleAnaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed Mod Rheumatol 15 201–3 Occurrence Handle17029063 Occurrence Handle10.1007/s10165-005-0386-x

    Article  PubMed  Google Scholar 

  46. JT Giles SJ Bartlett AC Gelber S Nanda K Fontaine V Ruffing et al. (2006) ArticleTitleTumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis Arthritis Care Res 55 333–7 Occurrence Handle10.1002/art.21841

    Article  Google Scholar 

  47. InstitutionalAuthorNameCenters for Disease Control and Prevention (2000) ArticleTitleTargeted tuberculin testing and treatment of latent tuberculosis infection MMWR 49 IssueIDNo. RR-6 26–39

    Google Scholar 

  48. InstitutionalAuthorNameBritish Thoracic Society Standards of Care Committee (2005) ArticleTitleBTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment Thorax 60 800–5 Occurrence Handle10.1136/thx.2005.046797

    Article  Google Scholar 

  49. F Vroom HEK De Walle MAJF Van de Laar JRBJ Brouwers LTW De Jong-van den Berg (2006) ArticleTitleDisease-modifying antirheumatic drugs in pregnancy Drug Safety 29 845–63 Occurrence Handle16970509 Occurrence Handle10.2165/00002018-200629100-00003 Occurrence Handle1:CAS:528:DC%2BD28XhtFyhs7zE

    Article  PubMed  CAS  Google Scholar 

  50. ES Sills M Perloe MJ Tucker CR Kaplan GD Palermo (2001) ArticleTitleSuccessful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis Am J Reprod Immunol 46 366–8 Occurrence Handle11712766 Occurrence Handle10.1034/j.1600-0897.2001.d01-25.x Occurrence Handle1:STN:280:DC%2BD3Mnms1Kmsw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  51. JA Katz C Antoni GF Keenan DE Smith SJ Jacobs GR Lichtenstein (2004) ArticleTitleOutcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis Am J Gastroenterol 99 2385–92 Occurrence Handle15571587 Occurrence Handle10.1111/j.1572-0241.2004.30186.x

    Article  PubMed  Google Scholar 

  52. KL Hyrich DPM Symmons KD Watson AJ Silman (2006) ArticleTitlePregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: result from a national population register Arthritis Rheum 54 2701–2 Occurrence Handle16871549 Occurrence Handle10.1002/art.22028

    Article  PubMed  Google Scholar 

  53. JE Salmon D Alpert (2006) ArticleTitleAre we coming to terms with tumor necrosis factor inhibition in pregnancy? Arthritis Rheum 54 2353–5 Occurrence Handle16868990 Occurrence Handle10.1002/art.22027 Occurrence Handle1:CAS:528:DC%2BD28XpsFGgu7o%3D

    Article  PubMed  CAS  Google Scholar 

  54. T Bongartz AJ Sutton MJ Sweeting I Buchan EL Matteson V Montori (2006) ArticleTitleAnti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies JAMA 295 2275–85 Occurrence Handle16705109 Occurrence Handle10.1001/jama.295.19.2275 Occurrence Handle1:CAS:528:DC%2BD28Xksl2ktrk%3D

    Article  PubMed  CAS  Google Scholar 

  55. J Askling CM Fored E Baecklund L Brandt C Backlin A Ekbom et al. (2005) ArticleTitleHaematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists Ann Rheum Dis 64 1414–20 Occurrence Handle15843454 Occurrence Handle10.1136/ard.2004.033241 Occurrence Handle1:STN:280:DC%2BD2MvptFCitg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  56. F Wolfe K Michaud (2004) ArticleTitleLymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 1740–51 Occurrence Handle15188349 Occurrence Handle10.1002/art.20311 Occurrence Handle1:CAS:528:DC%2BD2cXlsFaqt7Y%3D

    Article  PubMed  CAS  Google Scholar 

  57. EF Chakravarty K Michaud F Wolfe (2005) ArticleTitleSkin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors J Rheumatol 32 2130–5 Occurrence Handle16265690 Occurrence Handle1:CAS:528:DC%2BD2MXht12ltbvN

    PubMed  CAS  Google Scholar 

  58. P Geborek A Bladstrom C Turesson A Guffe IF Petersson T Saxne et al. (2005) ArticleTitleTumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas Ann Rheum Dis 64 699–703 Occurrence Handle15695534 Occurrence Handle10.1136/ard.2004.030528 Occurrence Handle1:CAS:528:DC%2BD2MXksFWrurc%3D

    Article  PubMed  CAS  Google Scholar 

  59. J Askling CM Fored L Brandt E Baecklund L Bertilsson N Feltelius et al. (2005) ArticleTitleRisk of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists Ann Rheum Dis 64 1421–6 Occurrence Handle15829572 Occurrence Handle10.1136/ard.2004.033993 Occurrence Handle1:STN:280:DC%2BD2MvptFCisw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  60. S Setoguchi DH Solomon ME Weinblatt JN Katz J Avorn RJ Glynn et al. (2006) ArticleTitleTumor necrosis factor α antagonist use and cancer in patients with rheumatoid arthritis Arthritis Rheum 54 2757–64 Occurrence Handle16947774 Occurrence Handle10.1002/art.22056 Occurrence Handle1:CAS:528:DC%2BD28XhtFWksLjO

    Article  PubMed  CAS  Google Scholar 

  61. EL Matteson AR Hickey L Maguire HH Tilson MB Urowitz (1991) ArticleTitleOccurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee J Rheumatol 18 809–14 Occurrence Handle1895261 Occurrence Handle1:STN:280:DyaK3MznsVCjsA%3D%3D

    PubMed  CAS  Google Scholar 

  62. L Mellemljaer MS Linet G Gridley M Frisch H Moller JH Olsen (1996) ArticleTitleRheumatoid arthritis and cancer risk Eur J Cancer 32A 1753–7 Occurrence Handle10.1016/0959-8049(96)00210-9

    Article  Google Scholar 

  63. P Tennis E Andrew C Bombardier Y Wang L Strand et al. (1993) ArticleTitleRecord linkage to conduct an epidemiologic study on the association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada J Clin Epidemiol 46 685–95 Occurrence Handle8326357 Occurrence Handle10.1016/0895-4356(93)90049-7 Occurrence Handle1:STN:280:DyaK3szhs1Whug%3D%3D

    Article  PubMed  CAS  Google Scholar 

  64. E Thomas DH Brewster RJ Black GJ Macfarlane (2000) ArticleTitleRisk of malignancy among patients with rheumatic conditions Int J Cancer 88 497–502 Occurrence Handle11054684 Occurrence Handle10.1002/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J Occurrence Handle1:STN:280:DC%2BD3crgsl2guw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  65. E Baecklund A Ekbom P Sparen N Feltelius L Klareskog (1998) ArticleTitleDisease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study Br Med J 317 180–1 Occurrence Handle1:STN:280:DyaK1czjt1KltA%3D%3D

    CAS  Google Scholar 

  66. E Baecklund A Iliadou J Askling A Ekbom C Backlin F Granath et al. (2006) ArticleTitleAssociation of chronic inflammation, not its treatment with increased lymphoma risk in rheumatoid arthritis Arthritis Rheum 54 692–701 Occurrence Handle16508929 Occurrence Handle10.1002/art.21675

    Article  PubMed  Google Scholar 

  67. E Salloum DL Cooper G Howe J Lacy G Tallini J Crouch et al. (1996) ArticleTitleSpontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases J Clin Oncol 14 1943–6 Occurrence Handle8656264 Occurrence Handle1:CAS:528:DyaK28XjslOrs7o%3D

    PubMed  CAS  Google Scholar 

  68. X Mariette D Cazals-Hatem J Warszawki F Liote N Balandraud J Sibilia et al. (2002) ArticleTitleLymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France Blood 99 3909–15 Occurrence Handle12010788 Occurrence Handle10.1182/blood.V99.11.3909 Occurrence Handle1:CAS:528:DC%2BD38XktFyrsrg%3D

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacovigilance, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Ryuji Koike

  2. Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan

    Ryuji Koike & Nobuyuki Miyasaka

  3. Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Tsutomu Takeuchi

  4. First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

    Katsumi Eguchi

Authors
  1. Ryuji Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsutomu Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katsumi Eguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nobuyuki Miyasaka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuji Koike.

About this article

Cite this article

Koike, R., Takeuchi, T., Eguchi, K. et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17, 451–458 (2007). https://doi.org/10.1007/s10165-007-0626-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-007-0626-3

Key words

Search

Navigation